Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 709049, 15 pages
http://dx.doi.org/10.1155/2012/709049
Review Article

Early Detection Biomarkers for Ovarian Cancer

1The Genomics and Biomarker Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA
2Genewiz, Inc., South Plainfield, NJ 07080, USA
3The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA

Received 19 June 2012; Accepted 19 November 2012

Academic Editor: William J. Hoskins

Copyright © 2012 Sreeja Sarojini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts & Figures 2012, American Cancer Society, Atlanta, Ga, USA, 2012.
  2. C. S. Chu and S. C. Rubin, “Screening for ovarian cancer in the general population,” Best Practice and Research Clinical Obstetrics and Gynaecology, vol. 20, no. 2, pp. 307–320, 2006. View at Google Scholar
  3. D. Badgwell and R. C. Bast Jr., “Early detection of ovarian cancer,” Disease Markers, vol. 23, no. 5-6, pp. 397–410, 2007. View at Google Scholar · View at Scopus
  4. I. J. Jacobs and U. Menon, “Progress and challenges in screening for early detection of ovarian cancer,” Molecular and Cellular Proteomics, vol. 3, no. 4, pp. 355–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. K. R. Cho and L. M. Shih, “Ovarian cancer,” Annual Review of Pathology, vol. 4, pp. 287–313, 2009. View at Publisher · View at Google Scholar
  6. A. Antoniou, P. D. P. Pharoah, S. Narod et al., “Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies,” American Journal of Human Genetics, vol. 72, no. 5, pp. 1117–1130, 2003. View at Publisher · View at Google Scholar
  7. A. C. Antoniou, A. P. Cunningham, J. Peto et al., “The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions,” British Journal of Cancer, vol. 98, no. 8, pp. 1457–1466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Chen, E. S. Iversen, T. Friebel et al., “Characterization of BRCA1 and BRCA2 mutations in a large United States sample,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 863–871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Gayther, W. Warren, S. Mazoyer et al., “Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation,” Nature Genetics, vol. 11, no. 4, pp. 428–433, 1995. View at Google Scholar · View at Scopus
  10. J. P. Struewing, P. Hartge, S. Wacholder et al., “The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews,” The New England Journal of Medicine, vol. 336, no. 20, pp. 1401–1408, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. R. C. Bast Jr., “Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 161–166, 2010. View at Publisher · View at Google Scholar
  12. K. S. Suh, S. W. Park, A. Castro et al., “Ovarian cancer biomarkers for molecular biosensors and translational medicine,” Expert Review of Molecular Diagnostics, vol. 10, no. 8, pp. 1069–1083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Høgdall, “Cancer antigen 125 and prognosis,” Current Opinion in Obstetrics and Gynecology, vol. 20, no. 1, pp. 4–8, 2008. View at Publisher · View at Google Scholar
  14. R. C. Bast Jr., T. L. Klug, E. S. John et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,” The New England Journal of Medicine, vol. 309, no. 15, pp. 883–887, 1983. View at Google Scholar · View at Scopus
  15. R. C. Bast Jr., D. Badgwell, Z. Lu et al., “New tumor markers: CA125 and beyond,” International Journal of Gynecological Cancer, vol. 15, no. 6, supplement 3, pp. 274–281, 2005. View at Google Scholar
  16. M. J. Duffy, J. M. Bonfrer, J. Kulpa et al., “CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use,” International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 679–691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Čolaković, V. Lukiç, L. Mitroviç, S. Jeliç, S. Šušnjar, and J. Marinkoviç, “Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer,” International Journal of Biological Markers, vol. 15, no. 2, pp. 147–152, 2000. View at Google Scholar
  18. B. J. D. Rein, S. Gupta, R. Dada, A. Agarwal, J. Safi, and C. Michener, “Potential markers for detection and monitoring of ovarian cancer,” Journal of Oncology, vol. 2011, Article ID 475983, 17 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. W. McIntosh, C. Drescher, B. Karlan et al., “Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma,” Gynecologic Oncology, vol. 95, no. 1, pp. 9–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. R.C. Bast Jr., F.-J. Xu, Y.-H. Yu, S. Barnhill, Z. Zhang, and G. B. Mills, “CA 125: the past and the future,” International Journal of Biological Markers, vol. 13, no. 4, pp. 179–187, 1998. View at Google Scholar
  21. A. E. Guppy and G. J. S. Rustin, “CA125 response: can it replace the traditional response criteria in ovarian cancer?” Oncologist, vol. 7, no. 5, pp. 437–443, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Tcherkassova, C. Abramovich, R. Moro et al., “Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer,” Tumor Biology, vol. 32, no. 4, pp. 831–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. R. G. Moore, D. S. McMeekin, A. K. Brown et al., “A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass,” Gynecologic Oncology, vol. 112, no. 1, pp. 40–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Jacobs, A. Gentry-Maharaj, M. Burnell et al., “Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort,” The Lancet Oncology, vol. 12, no. 1, pp. 38–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. U. Menon, A. Gentry-Maharaj, R. Hallett et al., “Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS),” The Lancet Oncology, vol. 10, no. 4, pp. 327–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Comamala, M. Pinard, C. Thériault et al., “Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells,” British Journal of Cancer, vol. 104, no. 6, pp. 989–999, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Thériault, M. Pinard, M. Comamala et al., “MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis,” Gynecologic Oncology, vol. 121, no. 3, pp. 434–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Dorigo and J. S. Berek, “Personalizing CA125 levels for ovarian cancer screening,” Cancer Prevention Research, vol. 4, no. 9, pp. 1356–1359, 2011. View at Publisher · View at Google Scholar
  29. S. J. Skates, P. Mai, N. K. Horick et al., “Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status,” Cancer Prevention Research, vol. 4, no. 9, pp. 1401–1408, 2011. View at Publisher · View at Google Scholar
  30. I. J. Jacobs, S. Skates, A. P. Davies et al., “Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study,” British Medical Journal, vol. 313, no. 7069, pp. 1355–1358, 1996. View at Google Scholar · View at Scopus
  31. C. Y. Muller, “Doctor, should I get this new ovarian cancer test-OVA1?” Obstetrics and Gynecology, vol. 116, no. 2, pp. 246–247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. F. R. Ueland, C. P. Desimone, L. G. Seamon et al., “Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors,” Obstetrics and Gynecology, vol. 117, no. 6, pp. 1289–1297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Hellstrom and K. E. Hellstrom, “SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other,” Advances in Experimental Medicine and Biology, vol. 622, pp. 15–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Heliström, J. Raycraft, M. Hayden-Ledbetter et al., “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,” Cancer Research, vol. 63, no. 13, pp. 3695–3700, 2003. View at Google Scholar · View at Scopus
  35. M. Montagnana, E. Danese, S. Giudici et al., “HE4 in ovarian cancer: from discovery to clinical application,” Advances in Clinical Chemistry, vol. 55, pp. 1–20, 2011. View at Publisher · View at Google Scholar
  36. R. G. Moore, M. C. Miller, P. Disilvestro et al., “Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass,” Obstetrics and Gynecology, vol. 118, no. 2, pp. 280–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Chang, X. Ye, L. Dong et al., “Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma,” International Journal of Gynecological Cancer, vol. 21, no. 5, pp. 852–858, 2011. View at Publisher · View at Google Scholar
  38. J. Li, S. Dowdy, T. Tipton et al., “HE4 as a biomarker for ovarian and endometrial cancer management,” Expert Review of Molecular Diagnostics, vol. 9, no. 6, pp. 555–566, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Molina, J. M. Escudero, J. M. Augé et al., “HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases,” Tumour Biology, vol. 32, no. 6, pp. 1087–1095, 2011. View at Google Scholar
  40. R. G. Moore, A. K. Brown, M. C. Miller et al., “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass,” Gynecologic Oncology, vol. 108, no. 2, pp. 402–408, 2008. View at Publisher · View at Google Scholar
  41. J. M. Escudero, J. M. Auge, X. Filella, A. Torne, J. Pahisa, and R. Molina, “Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases,” Clinical Chemistry, vol. 57, no. 11, pp. 1534–1544, 2011. View at Publisher · View at Google Scholar
  42. Z. Yurkovetsky, S. Skates, A. Lomakin et al., “Development of a multimarker assay for early detection of ovarian cancer,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2159–2166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Lu, X. Sun, R. Xiao, L. Zhou, X. Gao, and L. Guo, “Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility,” Biochemical and Biophysical Research Communications, vol. 419, no. 2, pp. 274–280, 2012. View at Publisher · View at Google Scholar
  44. A. J. Li, “New biomarkers for ovarian cancer: OVA1 and ROMA in diagnosis selective use of these new tests may lead to better outcomes for women with adnexal masses or epithelial ovarian cancer,” Contemporary Ob/Gyn, vol. 57, no. 4, 2012. View at Google Scholar
  45. F. Li, R. Tie, K. Chang et al., “Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: a meta-analysis,” BMC Cancer, vol. 12, article 258, 2012. View at Publisher · View at Google Scholar
  46. M. A. Karlsen, N. Sandhu, C. Høgdall et al., “Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass,” Gynecologic Oncology, vol. 127, no. 2, pp. 379–383, 2012. View at Publisher · View at Google Scholar
  47. R. Hassan, R. J. Kreitman, I. Pastan, and M. C. Willingham, “Localization of mesothelin in epithelial ovarian cancer,” Applied Immunohistochemistry and Molecular Morphology, vol. 13, no. 3, pp. 243–247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Hassan and M. Ho, “Mesothelin targeted cancer immunotherapy,” European Journal of Cancer, vol. 44, no. 1, pp. 46–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Scholler, B. Garvik, M. Hayden-Ledbetter, T. Kline, and N. Urban, “Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery,” Cancer Letters, vol. 247, no. 1-2, pp. 130–136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Rump, Y. Morikawa, M. Tanaka et al., “Binding of ovarian cancer antigen CA125/MUC61 to mesothelin mediates cell adhesion,” The Journal of Biological Chemistry, vol. 279, no. 10, pp. 9190–9198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. K. A. Lowe, C. Shah, E. Wallace et al., “Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 9, pp. 2480–2487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Y. Huang, W. F. Cheng, C. N. Lee et al., “Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor,” Anticancer Research, vol. 26, no. 6, pp. 4721–4728, 2006. View at Google Scholar · View at Scopus
  53. D. Badgwell, Z. Lu, L. Cole et al., “Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment,” Gynecologic Oncology, vol. 106, no. 3, pp. 490–497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. C. Chang, C. A. Chen, P. J. Chen et al., “Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways,” Biochemical Journal, vol. 442, no. 2, pp. 293–302, 2012. View at Publisher · View at Google Scholar
  55. E. P. Diamandis, A. Scorilas, S. Fracchioli et al., “Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma,” Journal of Clinical Oncology, vol. 21, no. 6, pp. 1035–1043, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. G. M. Yousef and E. P. Diamandis, “Expanded human tissue kallikrein family—a novel panel of cancer biomarkers,” Tumor Biology, vol. 23, no. 3, pp. 185–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. G. M. Yousef and E. P. Diamandis, “The new human tissue kallikrein gene family: structure, function, and association to disease,” Endocrine Reviews, vol. 22, no. 2, pp. 184–204, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. C. A. Borgoño, I. P. Michael, and E. P. Diamandis, “Human tissue kallikreins: physiologic roles and applications in cancer,” Molecular Cancer Research, vol. 2, no. 5, pp. 257–280, 2004. View at Google Scholar · View at Scopus
  59. A. Pavlopoulou, G. Pampalakis, I. Michalopoulos, and G. Sotiropoulou, “Evolutionary history of tissue kallikreins,” PLoS ONE, vol. 5, no. 11, Article ID e13781, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. O. A. Stone, C. Richer, C. Emanueli et al., “Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 5, pp. 657–664, 2009. View at Publisher · View at Google Scholar
  61. P. Dominek, P. Campagnolo, M. H. Zadeh et al., “Role of human tissue kallikrein in gastrointestinal stromal tumour invasion,” British Journal of Cancer, vol. 103, no. 9, pp. 1422–1431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. C. A. Borgoño and E. P. Diamandis, “The emerging roles of human tissue kallikreins in cancer,” Nature Reviews Cancer, vol. 4, no. 11, pp. 876–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Oikonomopoulou, K. K. Hansen, M. Saifeddine et al., “Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more,” Biological Chemistry, vol. 387, no. 6, pp. 677–685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Dong, A. Kaushal, L. Bui et al., “Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas,” Clinical Cancer Research, vol. 7, no. 8, pp. 2363–2371, 2001. View at Google Scholar · View at Scopus
  65. C. V. Obiezu, S. J. C. Shan, A. Soosaipillai et al., “Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids,” Clinical Chemistry, vol. 51, no. 8, pp. 1432–1442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. C. V. Obiezu, A. Scorilas, D. Katsaros et al., “Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients,” Clinical Cancer Research, vol. 7, no. 8, pp. 2380–2386, 2001. View at Google Scholar · View at Scopus
  67. C. V. Obiezu and E. P. Diamandis, “Human tissue kallikrein gene family: applications in cancer,” Cancer Letters, vol. 224, no. 1, pp. 1–22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Dong, A. Kaushal, M. Brattsand, J. Nicklin, and J. A. Clements, “Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers,” Clinical Cancer Research, vol. 9, no. 5, pp. 1710–1720, 2003. View at Google Scholar · View at Scopus
  69. S. J. C. Shan, A. Scorilas, D. Katsaros, and E. P. Diamandis, “Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects,” British Journal of Cancer, vol. 96, no. 2, pp. 362–372, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Emami and E. P. Diamandis, “Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers,” Clinical Chemistry, vol. 54, no. 10, pp. 1600–1607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. E. P. Diamandis, G. M. Yousef, A. R. Soosaipillai et al., “Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications,” Clinical Biochemistry, vol. 33, no. 5, pp. 369–375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. E. L. Ashby, P. G. Kehoe, and S. Love, “Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia,” Brain Research, vol. 1363, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. I. J. Jacobs, S. J. Skates, N. MacDonald et al., “Screening for ovarian cancer: a pilot randomised controlled trial,” The Lancet, vol. 353, no. 9160, pp. 1207–1210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. U. Kuzmanov, N. Jiang, C. R. Smith, A. Soosaipillai, and E. P. Diamandis, “Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system,” Molecular and Cellular Proteomics, vol. 8, no. 4, pp. 791–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. R. S. Henkhaus, U. K. B. Roy, D. Cavallo-Medved, B. F. Sloane, E. W. Gerner, and N. A. Ignatenko, “Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells,” Neoplasia, vol. 10, no. 2, pp. 140–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Talieri, E. P. Diamandis, D. Gourgiotis, K. Mathioudaki, and A. Scorilas, “Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma,” Thrombosis and Haemostasis, vol. 91, no. 1, pp. 180–186, 2004. View at Google Scholar · View at Scopus
  77. L. G. Kyriakopoulou, G. M. Yousef, A. Scorilas et al., “Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer,” Clinical Biochemistry, vol. 36, no. 2, pp. 135–143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Tanimoto, L. J. Underwood, K. Shigemasa et al., “The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells,” Cancer, vol. 86, no. 10, pp. 2074–2082, 1999. View at Publisher · View at Google Scholar
  79. T. Kishi, L. Grass, A. Soosaipillai, C. Shimizu-Okabe, and E. P. Diamandis, “Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids,” Clinical Chemistry, vol. 49, no. 1, pp. 87–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. L. M. Shih, R. Salani, M. Fiegl et al., “Ovarian cancer specific kallikrein profile in effusions,” Gynecologic Oncology, vol. 105, no. 2, pp. 501–507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. S. C. L. Koh, K. Razvi, Y. H. Chan et al., “The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer,” Archives of Gynecology and Obstetrics, vol. 284, no. 1, pp. 183–190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Pépin, Z. Q. Shao, G. Huppé et al., “Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model,” PLoS ONE, vol. 6, no. 11, Article ID e26075, 2011. View at Publisher · View at Google Scholar
  83. E. P. Diamandis, G. M. Yousef, L. Y. Luo, A. Magklara, and C. V. Obiezu, “The new human kallikrein gene family: implications in carcinogenesis,” Trends in Endocrinology and Metabolism, vol. 11, no. 2, pp. 54–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. H. S. Shvartsman, K. H. Lu, J. Lee et al., “Overexpression of kallikrein 10 in epithelial ovarian carcinomas,” Gynecologic Oncology, vol. 90, no. 1, pp. 44–50, 2003. View at Publisher · View at Google Scholar
  85. U. R. Jag, R. Gharbaran, T. Tanaka et al., “Kallikrein family proteases KLK6 and KLK7 are early detection and diagnostic biomarkers for serous and papillary serous subtypes of ovarian cancer,” Cancer Biomarkers. In press.
  86. J. X. Yu, L. Chao, and J. Chao, “Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland,” The Journal of Biological Chemistry, vol. 269, no. 29, pp. 18843–18848, 1994. View at Google Scholar · View at Scopus
  87. J. X. Yu, L. Chao, D. C. Ward, and J. Chao, “Structure and chromosomal localization of the human prostasin (PRSS8) gene,” Genomics, vol. 32, no. 3, pp. 334–340, 1996. View at Publisher · View at Google Scholar · View at Scopus
  88. G. M. Verghese, M. F. Gutknecht, and G. H. Caughey, “Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor,” American Journal of Physiology, vol. 291, no. 6, pp. C1258–C1270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Friis, S. Godiksen, J. Bornholdt et al., “Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase,” The Journal of Biological Chemistry, vol. 286, no. 7, pp. 5793–5802, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. Y. Fu, W. L. Gao, M. Chen, K. X. Chai, Y. L. Wang, and L. M. Chen, “Prostasin regulates human placental trophoblast cell proliferation via the epidermal growth factor receptor signaling pathway,” Human Reproduction, vol. 25, no. 3, pp. 623–632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. S. C. Mok, J. Chao, S. Skates et al., “Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology,” Journal of the National Cancer Institute, vol. 93, no. 19, pp. 1458–1464, 2001. View at Google Scholar · View at Scopus
  92. F. P. Costa, E. L. Batista Jr., A. Zelmanowicz et al., “Prostasin, a potential tumor marker in ovarian cancer—a pilot study,” Clinics, vol. 64, no. 7, pp. 641–644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Sun, J. Qin, Y. Qiu et al., “Microarray analysis of gene expression in the ovarian cancer cell line HO-8910 with silencing of the ZNF217 gene,” Molecular Medicine Reports, vol. 2, no. 5, pp. 851–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Chen, L. M. Chen, C. Y. Lin, and K. X. Chai, “The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells,” Biochimica et Biophysica Acta, vol. 1783, no. 5, pp. 896–903, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Rahilly, P. J. Carder, A. Al Nafussi, and D. J. Harrison, “Distribution of glutathione S-transferase isoenzymes in human ovary,” Journal of Reproduction and Fertility, vol. 93, no. 2, pp. 303–311, 1991. View at Google Scholar · View at Scopus
  96. S. S. Coughlin and I. J. Hall, “Glutathione S-transferase polymorphisms and risk of ovarian cancer: a HuGE review,” Genetics in Medicine, vol. 4, no. 4, pp. 250–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Beeghly, D. Katsaros, H. Chen et al., “Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival,” Gynecologic Oncology, vol. 100, no. 2, pp. 330–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. K. P. Economopoulos, T. N. Sergentanis, and N. F. Vlahos, “Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis,” International Journal of Gynecological Cancer, vol. 20, no. 5, pp. 732–737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. D. M. Townsend, K. D. Tew, and H. Tapiero, “The importance of glutathione in human disease,” Biomedicine and Pharmacotherapy, vol. 57, no. 3, pp. 145–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. R. E. J. Howells, C. W. E. Redman, K. K. Dhar et al., “Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer,” Clinical Cancer Research, vol. 4, no. 10, pp. 2439–2445, 1998. View at Google Scholar · View at Scopus
  101. R. E. J. Howells, T. Holland, K. K. Dhar et al., “Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival,” International Journal of Gynecological Cancer, vol. 11, no. 2, pp. 107–112, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. C. C. McIlwain, D. M. Townsend, and K. D. Tew, “Glutathione S-transferase polymorphisms: cancer incidence and therapy,” Oncogene, vol. 25, no. 11, pp. 1639–1648, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. K. D. Tew, Y. Manevich, C. Grek, Y. Xiong, J. Uys, and D. M. Townsend, “The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer,” Free Radical Biology and Medicine, vol. 51, no. 2, pp. 299–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. L. A. Dainty, J. I. Risinger, C. Morrison et al., “Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma,” Gynecologic Oncology, vol. 105, no. 3, pp. 563–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. L. E. Kelemen, “The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander?” International Journal of Cancer, vol. 119, no. 2, pp. 243–250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. L. Chen, M. C. Chang, C. Y. Huang et al., “Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response,” Molecular Oncology, vol. 6, no. 3, pp. 360–369, 2012. View at Publisher · View at Google Scholar
  107. G. M. van Dam, G. Themelis, L. M. A. Crane et al., “Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results,” Nature Medicine, vol. 17, no. 10, pp. 1315–1319, 2011. View at Publisher · View at Google Scholar
  108. Y. Yuan, D. A. Nymoen, H. P. Dong et al., “Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions,” Human Pathology, vol. 40, no. 10, pp. 1453–1460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Wu, W. Gunning, and M. Ratnam, “Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix,” Cancer Epidemiology Biomarkers and Prevention, vol. 8, no. 9, pp. 775–782, 1999. View at Google Scholar · View at Scopus
  110. E. Basal, G. Z. Eghbali-Fatourechi, K. R. Kalli et al., “Functional folate receptor alpha is elevated in the blood of ovarian cancer patients,” PLoS ONE, vol. 4, no. 7, Article ID e6292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Markert, S. Lassmann, B. Gabriel et al., “Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue,” Anticancer Research, vol. 28, no. 6A, pp. 3567–3572, 2008. View at Google Scholar · View at Scopus
  112. K. R. Kalli, A. L. Oberg, G. L. Keeney et al., “Folate receptor alpha as a tumor target in epithelial ovarian cancer,” Gynecologic Oncology, vol. 108, pp. 619–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. L. M. Crane, H. J. Arts, M. van Oosten et al., “The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer,” Cellular Oncology, vol. 35, no. 1, pp. 9–18, 2012. View at Google Scholar
  114. S. Miotti, M. Bagnoli, A. Tomassetti, M. I. Colnaghi, and S. Canevari, “Interaction of folate receptor with signaling molecules lyn and Gα(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1,” Journal of Cell Science, vol. 113, no. 2, pp. 349–357, 2000. View at Google Scholar · View at Scopus
  115. M. T. M. van Jaarsveld, J. Helleman, E. M. J. J. Berns, and E. A. C. Wiemer, “MicroRNAs in ovarian cancer biology and therapy resistance,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 8, pp. 1282–1290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. M. V. Iorio, R. Visone, G. Di Leva et al., “MicroRNA signatures in human ovarian cancer,” Cancer Research, vol. 67, no. 18, pp. 8699–8707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. D. D. Taylor and C. Gercel-Taylor, “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer,” Gynecologic Oncology, vol. 110, no. 1, pp. 13–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. X. Hu, D. M. Macdonald, P. C. Huettner et al., “A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer,” Gynecologic Oncology, vol. 114, no. 3, pp. 457–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Yang, W. Kong, L. He et al., “MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN,” Cancer Research, vol. 68, no. 2, pp. 425–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. Z. Li, S. Hu, J. Wang et al., “MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells,” Gynecologic Oncology, vol. 119, no. 1, pp. 125–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. B. Chang, G. Liu, F. Xue et al., “ALDH1 expression correlates with favorable prognosis in ovarian cancers,” Modern Pathology, vol. 22, no. 6, pp. 817–823, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. K. D. Steffensen, A. B. Alvero, Y. Yang et al., “Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer,” Journal of Oncology, vol. 2011, Article ID 620523, 12 pages, 2011. View at Publisher · View at Google Scholar
  123. I. A. Silva, S. Bai, K. McLean et al., “Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival,” Cancer Research, vol. 71, no. 11, pp. 3991–4001, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. C. N. Landen Jr., B. Goodman, A. A. Katre et al., “Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer,” Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3186–3199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. K. Penumatsa, S. L. Edassery, A. Barua, M. J. Bradaric, and J. L. Luborsky, “Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors,” Journal of Ovarian Research, vol. 3, no. 1, article 28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Deng, X. Yang, H. Lassus et al., “Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers,” PLoS ONE, vol. 5, no. 4, Article ID e10277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. J. Kurebayashi, N. Kanomata, T. Moriya, Y. Kozuka, M. Watanabe, and H. Sonoo, “Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype,” BMC Cancer, vol. 10, article 568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Chatterjee and M. A. Tainsky, “Autoantibodies as biomarkers for ovarian cancer,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 187–201, 2010. View at Publisher · View at Google Scholar
  129. C. Li, D. Sasaroli, X. Chen et al., “Tumor vascular biomarkers: new opportunities for cancer diagnostics,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 253–271, 2010. View at Publisher · View at Google Scholar
  130. R. J. Buckanovich, D. Sasaroli, A. O'Brien-Jenkins et al., “Tumor vascular proteins as biomarkers in ovarian cancer,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 852–861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. K. L. Abbott, “Glycomic analysis of ovarian cancer: past, present, and future,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 273–280, 2010. View at Publisher · View at Google Scholar
  132. H. J. An and C. B. Lebrilla, “A glycomics approach to the discovery of potential cancer biomarkers,” Methods in Molecular Biology, vol. 600, pp. 199–213, 2010. View at Google Scholar · View at Scopus
  133. C. D. Roberson, S. Atay, C. Gercel-Taylor, and D. D. Taylor, “Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 281–287, 2010. View at Publisher · View at Google Scholar
  134. E. Nowosinska, S. Avril, I. Murray, T. Szyszko, and N. Avril, “FDG-PET/CT as a molecular biomarker in ovarian cancer,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 167–175, 2010. View at Publisher · View at Google Scholar
  135. Y. H. Lin and H. F. Yang-Yen, “The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway,” The Journal of Biological Chemistry, vol. 276, no. 49, pp. 46024–46030, 2001. View at Publisher · View at Google Scholar · View at Scopus
  136. I. Simon, D. Katsaros, I. Rigault de la Longrais et al., “B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression,” Gynecologic Oncology, vol. 106, no. 2, pp. 334–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. I. Simon, S. Zhuo, L. Corral et al., “B7-H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer,” Cancer Research, vol. 66, no. 3, pp. 1570–1575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. J. H. Kim, S. J. Skates, T. Uede et al., “Osteopontin as a potential diagnostic biomarker for ovarian cancer,” The Journal of the American Medical Association, vol. 287, no. 13, pp. 1671–1679, 2002. View at Google Scholar · View at Scopus
  139. J. Dupont, M. K. Tanwar, H. T. Thaler et al., “Early detection and prognosis of ovarian cancer using serum YKL-40,” Journal of Clinical Oncology, vol. 22, no. 16, pp. 3330–3339, 2004. View at Publisher · View at Google Scholar · View at Scopus
  140. S. F. M. Häusler, A. Keller, P. A. Chandran et al., “Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening,” British Journal of Cancer, vol. 103, no. 5, pp. 693–700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. C. A. Shah, K. A. Lowe, P. Paley et al., “Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 5, pp. 1365–1372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. S. R. Lakhani, S. Manek, F. Penault-Llorca et al., “Pathology of ovarian cancers in BRCA1 and BRCA2 carriers,” Clinical Cancer Research, vol. 10, no. 7, pp. 2473–2481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  143. C. Loveday, C. Turnbull, E. Ramsay et al., “Germline mutations in RAD51D confer susceptibility to ovarian cancer,” Nature Genetics, vol. 43, no. 9, pp. 879–882, 2011. View at Publisher · View at Google Scholar
  144. D. Bell, A. Berchuck, M. Birrer et al., “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011. View at Publisher · View at Google Scholar
  145. G. Singer, R. Oldt, Y. Cohen et al., “Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 6, pp. 484–486, 2003. View at Google Scholar · View at Scopus
  146. J. Palacios and C. Gamallo, “Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas,” Cancer Research, vol. 58, no. 7, pp. 1344–1347, 1998. View at Google Scholar · View at Scopus
  147. K. T. Kuo, T. L. Mao, S. Jones et al., “Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma,” American Journal of Pathology, vol. 174, no. 5, pp. 1597–1601, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. K. C. Wiegand, S. P. Shah, O. M. Al-Agha et al., “ARID1A mutations in endometriosis-associated ovarian carcinomas,” The New England Journal of Medicine, vol. 363, no. 16, pp. 1532–1543, 2010. View at Publisher · View at Google Scholar
  149. A. Heravi-Moussavi, M. S. Anglesio, S.-W. G. Cheng et al., “Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers,” The New England Journal of Medicine, vol. 366, no. 3, pp. 234–242, 2012. View at Publisher · View at Google Scholar
  150. B. M. Nolen and A. E. Lokshin, “Screening for ovarian cancer: old tools, new lessons,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 177–186, 2010. View at Publisher · View at Google Scholar